摘要
目的评价二甲双胍减轻第二代抗精神病药物（senond—generation antipsychotics，SGA）所致精神分裂症患者体质量增高的干预效果。方法计算机检索Cochrane Library、Medline、万方数据库、CNKI、维普中文期刊数据库（VIP）以及中国学位论文全文数据库，收集1998年1月至2012年7月关于二甲双胍减轻SGA所致精神分裂症患者体质量增高的随机对照试验（Randomized Controlled Trials，RCT）。由两位研究者独立进行文献筛选、资料提取和方法学质量评价后，采用RevMan5．1和Stata12．0软件进行Meta分析。结果7篇随机对照研究满足纳入标准，包括394名受试者。Meta分析结果显示：二甲双胍组干预体质量的效果与对照组比较，均数差为MD=-3．07，95％CI为（-4．17，-1．98），差异有统计学意义（Z=5．50，P〈0．01）；二甲双胍组干预BWI的效果与对照组比较，均数差为MD=-1．21，95％CI为（-1．50，-0．92），差异有统计学意义（Z=8．18，P〈0．01）。结论二甲双胍能有效减轻第二代抗精神病药物所致的精神分裂症患者体质量增高。
Objective To assess whether metformin prevents body weight gain in patients with schizophrenia who are treated with second-generation antipsychotics （SGA）. Methods The randomized controlled trials （RCT） about metformin for prevention of weight gain with SGA for schizophrenia from January 1998 to July 2012 were selected in the Cochrane Library, Medline, Wanfang Data, CNKI and VIP. Two reviewers independently screened the literatures, extracted the data, and evaluated the methodological quality. Than meta-analyses were conducted by using RevMan 5.1 software and Stata 12.0 software. Results The total 7 RCTs were selected and 394 patients were involved. The results of meta-analyses showed that the efficacy of the metformin group was superior to that of the control group in lessen body mass （ MD = - 3.07,95% CI ： - 4.17, - 1.98, Z = 5.50, P 〈 0.01 ）, BWI （MD = - 1.21,95% CI ： - 1.50, -0. 92, Z= 8.18, P〈 0.01 ） with significant differences. Conclusion Metformin addition therapy is effective in attenuating SGA-induced weight gain.
出处
《中华行为医学与脑科学杂志》
CAS
CSCD
北大核心
2013年第3期221-224,共4页
Chinese Journal of Behavioral Medicine and Brain Science
